Literature DB >> 2311444

Transintestinal elimination of ciprofloxacin.

R Rohwedder1, T Bergan, S B Thorsteinsson, H Scholl.   

Abstract

This study elucidates the routes of elimination of ciprofloxacin and its metabolites in two groups of 5 subjects each, one of healthy volunteers, the other of patients with severe renal failure having a creatinine clearance of 12 ml/min (range 8-16 ml/min). Each subject received one dose of 200 mg ciprofloxacin infused intravenously over 30 min. In an effort to recover the total dose administered, all urine and faeces were collected for the 7 days following dosing. Blood was collected at set intervals after dosing. Serum, urine, and faeces were assayed by high-pressure liquid chromatography for ciprofloxacin and metabolites. The ciprofloxacin serum half-life in healthy volunteers was 3.9 +/- 0.4 h and in patients with marked renal failure 11.2 +/- 2.5 h. The total amount of ciprofloxacin recovered in urine fell by a multiple of 3.4 from 65.3 +/- 10.7% in healthy subjects to 19.0 +/- 15.9% in patients with renal failure, and the metabolites from 12.2 +/- 2.3% in the former group to 5.8 +/- 5.1% in the latter. In contrast, the amount of ciprofloxacin eliminated in faeces increased, by a similar factor, from 11.4 +/- 2.6% in healthy subjects to 37.2 +/- 12.5% in patients with renal failure. The amount of metabolites in faeces increased analogously from 7.3 +/- 1.6 to 26.2 +/- 6.5%. Since ciprofloxacin was administered intravenously and biliary elimination of the drug and its metabolites is negligible, we propose that elimination by faeces is due primarily to transintestinal elimination. This study demonstrates that transintestinal elimination of ciprofloxacin serves as an extrarenal safety factor compensating for reduced elimination by the renal route.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2311444     DOI: 10.1159/000238751

Source DB:  PubMed          Journal:  Chemotherapy        ISSN: 0009-3157            Impact factor:   2.544


  26 in total

1.  Influence of renal failure on intestinal clearance of ciprofloxacin in rats.

Authors:  S Dautrey; L Rabbaa; D Laouari; B Lacour; C Carbon; R Farinotti
Journal:  Antimicrob Agents Chemother       Date:  1999-03       Impact factor: 5.191

2.  Influence of activated charcoal on the pharmacokinetics of moxifloxacin following intravenous and oral administration of a 400 mg single dose to healthy males.

Authors:  H Stass; D Kubitza; J-G Möller; H Delesen
Journal:  Br J Clin Pharmacol       Date:  2005-05       Impact factor: 4.335

3.  Meropenem dosing in critically ill patients with sepsis receiving high-volume continuous venovenous hemofiltration.

Authors:  I Bilgrami; J A Roberts; S C Wallis; J Thomas; J Davis; S Fowler; P B Goldrick; J Lipman
Journal:  Antimicrob Agents Chemother       Date:  2010-05-17       Impact factor: 5.191

4.  Active intestinal elimination of ciprofloxacin in rats: modulation by different substrates.

Authors:  S Dautrey; K Felice; A Petiet; B Lacour; C Carbon; R Farinotti
Journal:  Br J Pharmacol       Date:  1999-08       Impact factor: 8.739

5.  Temafloxacin pharmacokinetics in subjects with normal and impaired renal function.

Authors:  G R Granneman; R Braeckman; J Kraut; S Shupien; J C Craft
Journal:  Antimicrob Agents Chemother       Date:  1991-11       Impact factor: 5.191

Review 6.  Requirements for the documentation of pharmacokinetic properties of antimicrobial agents.

Authors:  T Bergan
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-07       Impact factor: 3.267

7.  Oral ciprofloxacin in the treatment of cholera.

Authors:  E Gotuzzo; C Seas; J Echevarria; R Ruiz; C Carrillo
Journal:  Drugs       Date:  1995       Impact factor: 9.546

Review 8.  Impact of the fluoroquinolones on gastrointestinal flora.

Authors:  V Korten; B E Murray
Journal:  Drugs       Date:  1993       Impact factor: 9.546

9.  Biliary excretion of rufloxacin in humans.

Authors:  G Privitera; G Nicastro; B P Imbimbo; M Cesana; M Visconti; F Lombardi; G Tagliabue; E Faleschini; F Colturani; P Franzini
Journal:  Antimicrob Agents Chemother       Date:  1993-12       Impact factor: 5.191

10.  Active secretion of the fluoroquinolone ciprofloxacin by human intestinal epithelial Caco-2 cell layers.

Authors:  N M Griffiths; B H Hirst; N L Simmons
Journal:  Br J Pharmacol       Date:  1993-03       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.